Why the study?
While historically aggressive, some synovial sarcomas are clinically indolent, raising the question of whether tumor grade predicts oncologic outcomes and whether Grade 1 disease exists.
Does synovial sarcoma grade predict oncologic outcomes, and does a low-grade variant exist?
Does synovial sarcoma grade predict oncologic outcomes, and does a low-grade variant exist?
Tumor grade in synovial sarcoma appears to predict oncologic outcomes, with a theoretical Grade 1 group showing improved survival profiles compared to Grades 2 and 3.
Answers are grounded in this paper and cite their sources.
Grade 3 synovial sarcoma was associated with worse metastasis-free survival; supports grading as prognostic but leaves open distinct low-grade variants.
BACKGROUND AND OBJECTIVES: While historically aggressive, some synovial sarcomas (SS) are clinically indolent. This study sought to determine whether SS grade predicts oncologic outcomes and whether Grade 1 disease might exist. METHODS: Thirty-five cases from 2010 to 2019 were retrospectively reviewed. Clinicopathological data were analyzed and Kaplan-Meier assessed survival. RESULTS: The median patient age was 37 years (interquartile range: 28-51.5). The local control rate was 74.3%, and recurrence-free survival (RFS) was worse in positive versus negative margin resections (p = 0.023). The incidence of metastasis was 21.9% (n = 7) at a median 31 ± 31.7 months, and metastasis-free survival was 50.0% in Grade 3 SS versus 86.5% in Grade 2 (p = 0.026). Among a theoretical Grade 1 group, the overall survival (OS) and RFS profiles were improved compared to Grade 2 and 3 SS, respectively (p = 0.014 and p = 0.030). The Grade 1 group had a 15.8% (n = 3) metastatic rate and 80% 10-year survival. CONCLUSIONS: Tumor grade appears to predict outcomes in SS. A theoretical Grade 1 group showed improved OS and RFS versus Grades 2 and 3 SS, with metastatic rates and long-term survival resembling the historical literature for other low-grade soft tissue sarcomas. Our group continues to support the French Federation of Cancer Centers diagnostic strategy and NCCN treatment guidelines for SS.
No takes yet. Share an insight, caveat, or question.
Fice et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: